<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096694</url>
  </required_header>
  <id_info>
    <org_study_id>A5205</org_study_id>
    <secondary_id>10187</secondary_id>
    <secondary_id>ACTG A5205</secondary_id>
    <nct_id>NCT00096694</nct_id>
  </id_info>
  <brief_title>Effect of an Intrauterine Contraceptive Device (IUD) in HIV Infected Women</brief_title>
  <official_title>A Pilot Study Evaluating the Effect of the Levonorgestrel-Releasing Intrauterine Device on Genital HIV Shedding in HIV-1-Infected Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Oral contraceptives (OCs) are not a good option for some HIV infected women because of the
      potential for drug interactions between OCs and anti-HIV drugs; additionally, OCs may
      increase the risk of transmitting HIV to sexual partners. Levonorgestrel is commonly
      prescribed as part of a combination OC. An intrauterine device (IUD) is a device inserted in
      a woman's uterus to prevent pregnancy. The purpose of this study is to determine the effect
      of a levonorgestrel-releasing IUD on the amount of HIV present in an HIV infected woman's
      cervix after 4 weeks of IUD use.

      Study hypothesis: There will be no increase in genital tract HIV RNA and DNA after placement
      of the levonorgestrel IUD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV infected women face the challenges of preventing both pregnancy and HIV transmission to
      their sexual partners. However, OCs may interact with antiretroviral therapy (ART), and data
      suggest that higher doses of OCs may increase cervical shedding of HIV-1, which may increase
      an HIV infected woman's infectiousness to her sexual partners. A physical barrier
      contraceptive would be useful to HIV infected women to circumvent the problems associated
      with concurrent use of OCs and ART. The levonorgestrel IUD has proved highly effective in
      preventing unwanted pregnancies in HIV uninfected women since its introduction in the United
      States in 1999. This study will evaluate the effect of the levonorgestrel IUD on HIV viral
      load in an HIV infected woman's cervix after 4 weeks of IUD use.

      This study will last approximately 48 weeks; there will be 4 study visits. At screening,
      participants will undergo medical and medication history assessment; a complete physical
      exam; a pelvic exam, including genital tract sample collection; blood collection; sexually
      transmitted disease (STD) testing; and a Pap smear, if needed. The levonorgestrel IUD will be
      inserted into the participant's uterus at study entry. At study entry and at Weeks 4, 16, and
      48, participants will undergo a targeted physical exam; a pelvic exam, including genital
      tract sample collection; and blood collection. Participants will be given a menstrual diary
      at the start of the study and at each study visit and will be asked to document all menstrual
      cycles they have for the duration of the study.

      To be eligible for this study, participants may not have had ART within 90 days prior to
      study entry. However, after the Week 4 study visit, participants may reinitiate (if they were
      on ART more than 90 days prior to study entry) or initiate (if they are ART naive) ART, if
      deemed necessary to do so by their physicians.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">September 2005</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sign and magnitude of difference in endocervical HIV viral load from baseline to Week 4 post-IUD insertion</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of discontinuation of IUD use in the year following insertion</measure>
  </primary_outcome>
  <enrollment>41</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Levonorgestrel-releasing intrauterine device (IUD)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected

          -  Willing and able to delay initiation or reinitiation of antiretroviral therapy until
             after Week 4 study visit

          -  Unlikely to develop a clinical indication to start antiretroviral therapy within 4
             weeks of study entry

          -  CD4 count of 200 cells/mm3 or more

          -  Viral load of 10,000 copies/ml or more within 90 days prior to study entry

          -  Endocervical viral load of 2,500 copies/ml or more within 90 days prior to study entry

          -  History of prior pregnancy lasting at least 20 weeks

          -  Willing to continue any current use of hormonal contraceptives, except
             medroxyprogesterone acetate, until after Week 4 study visit

          -  Start of last menstrual period within 7 days prior to study entry

        Exclusion Criteria:

          -  Antiretroviral medications within 90 days prior to study entry

          -  AIDS diagnosis, including CD4 count of less than 200 cells/mm3

          -  Cervicitis, bacterial vaginosis, trichomoniasis, or symptomatic vaginal candidiasis
             within 90 days prior to study entry. Participants with any of these infections within
             90 days prior to study entry are not excluded if they have received appropriate
             treatment and have documented resolution of the infection.

          -  Acute or history of pelvic inflammatory disease, chlamydia, or gonorrhea in the year
             prior to study entry

          -  Abnormal Pap smear requiring treatment in the year prior to study entry

          -  History of ectopic pregnancy or a condition that would predispose the participant to
             ectopic pregnancy

          -  Known uterine anomaly, including fibroids

          -  Known or suspected breast cancer

          -  Acute liver disease or liver tumor

          -  Have previously inserted IUD that has not been removed

          -  Fungal infection in the genitals

          -  Genital bleeding of unknown cause

          -  Endometritis or infected abortion within 90 days of study entry

          -  Known allergy or hypersensitivity to any component of the IUD used in this study

          -  Current drug or alcohol abuse that, in the opinion of the investigator, may interfere
             with the study

          -  Serious infection or other serious medical illness that is potentially life
             threatening and requires systemic therapy or hospitalization within 14 days of study
             entry

          -  Use of etonogestrel and ethinyl estradiol vaginal ring (NuvaRing) within 30 days prior
             to study entry

          -  Medroxyprogesterone acetate within 90 days prior to study entry

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Milu Kojic, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Immunology/Infectious Disease, The Miriam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>77555-0435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IHV Baltimore Treatment CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SSTAR, Family Healthcare Ctr.</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med. Ctr., ACTU</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ. Med. Ctr. Adult CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hosp.</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hosp. ACTG CRS</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puerto Rico-AIDS CRS</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bird ST, Harvey SM, Maher JE, Beckman LJ. Acceptability of an existing, female-controlled contraceptive method that could potentially protect against HIV: a comparison of diaphragm users and other method users. Womens Health Issues. 2004 May-Jun;14(3):85-93.</citation>
    <PMID>15193636</PMID>
  </reference>
  <reference>
    <citation>Richardson BA, Morrison CS, Sekadde-Kigondu C, Sinei SK, Overbaugh J, Panteleeff DD, Weiner DH, Kreiss JK. Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS. 1999 Oct 22;13(15):2091-7.</citation>
    <PMID>10546862</PMID>
  </reference>
  <reference>
    <citation>Stuart GS, Casta√±o PM. Sexually transmitted infections and contraceptives: selective issues. Obstet Gynecol Clin North Am. 2003 Dec;30(4):795-808. Review.</citation>
    <PMID>14719851</PMID>
  </reference>
  <reference>
    <citation>Wang CC, McClelland RS, Overbaugh J, Reilly M, Panteleeff DD, Mandaliya K, Chohan B, Lavreys L, Ndinya-Achola J, Kreiss JK. The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS. 2004 Jan 23;18(2):205-9.</citation>
    <PMID>15075537</PMID>
  </reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2004</study_first_submitted>
  <study_first_submitted_qc>November 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2004</study_first_posted>
  <last_update_submitted>May 17, 2012</last_update_submitted>
  <last_update_submitted_qc>May 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intrauterine Device</keyword>
  <keyword>IUD</keyword>
  <keyword>Contraceptive</keyword>
  <keyword>Levonorgestrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

